Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.57 USD | -3.97% | -6.70% | -1.42% |
May. 09 | Stifel Adjusts Price Target on C4 Therapeutics to $14 From $13, Maintains Buy Rating | MT |
May. 08 | C4 Therapeutics Shares Decline as Q1 Revenue Misses Estimates | MT |
Financials (USD)
Sales 2024 * | 25.7M | Sales 2025 * | 20.24M | Capitalization | 383M |
---|---|---|---|---|---|
Net income 2024 * | -116M | Net income 2025 * | -149M | EV / Sales 2024 * | 3.34 x |
Net cash position 2024 * | 297M | Net cash position 2025 * | 286M | EV / Sales 2025 * | 4.8 x |
P/E ratio 2024 * |
-3.47
x | P/E ratio 2025 * |
-2.92
x | Employees | 145 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.26% |
Latest transcript on C4 Therapeutics, Inc.
1 day | -3.97% | ||
1 week | -6.70% | ||
Current month | -11.59% | ||
1 month | -19.28% | ||
3 months | -38.04% | ||
6 months | +266.45% | ||
Current year | -1.42% |
Managers | Title | Age | Since |
---|---|---|---|
Andrew Hirsch
CEO | Chief Executive Officer | 53 | 20-09-13 |
Kendra Adams
DFI | Director of Finance/CFO | 48 | 20-11-19 |
Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bruce Downey
CHM | Chairman | 76 | 15-11-30 |
Glenn Dubin
BRD | Director/Board Member | 67 | 21-03-11 |
Bihua Chen
PRN | Corporate Officer/Principal | 55 | 15-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 5.57 | -3.97% | 1,155,851 |
24-05-22 | 5.8 | +0.69% | 787,448 |
24-05-21 | 5.76 | +2.49% | 891,124 |
24-05-20 | 5.62 | -1.06% | 876,082 |
24-05-17 | 5.68 | -4.86% | 1,255,738 |
Delayed Quote Nasdaq, May 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.42% | 383M | |
+64.92% | 62.86B | |
-1.85% | 41.38B | |
+44.76% | 40.38B | |
-8.93% | 27.64B | |
+13.05% | 26.46B | |
-21.96% | 18.9B | |
+4.21% | 12.67B | |
+25.74% | 12.27B | |
+27.42% | 12.07B |
- Stock Market
- Equities
- CCCC Stock